^
BIOMARKER:

FLT3 mutation

i
Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2
Entrez ID:
FLT3 mutation
Leukemia
midostaurin
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
FLT3 mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3 mutation
AML
midostaurin + gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
FLT3 mutation
AML
venetoclax
Sensitive: A2 - Guideline
FLT3 mutation
AML
FLT3 inhibitor
Sensitive: B - Late Trials
FLT3 mutation
AML
venetoclax + azacitidine
Sensitive: B - Late Trials
FLT3 mutation
AML
quizartinib + RAIN-32
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
sunitinib
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
quizartinib
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
Hypomethylating agent + venetoclax
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
ARO-002
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
CEP-701
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
MDS
ARO-002
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
sorafenib
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
azacitidine
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
FLT3 inhibitor + gilteritinib
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
MDS
quizartinib
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
venetoclax + midostaurin
Sensitive: C3 – Early Trials
FLT3 mutation
AML
venetoclax + sorafenib
Sensitive: C3 – Early Trials
FLT3 mutation
NSCLC
nintedanib
Sensitive: C3 – Early Trials
FLT3 mutation
AML
ivosidenib
Resistant: C3 – Early Trials
FLT3 mutation
AML
cytarabine + clofarabine
Sensitive: C3 – Early Trials
FLT3 mutation
AML
cytarabine + cladribine
Sensitive: C3 – Early Trials
FLT3 mutation
AML
decitabine + clofarabine
Sensitive: C3 – Early Trials
FLT3 mutation
AML
decitabine + cladribine
Sensitive: C3 – Early Trials
FLT3 mutation
AML
FLT3 inhibitor + venetoclax + decitabine
Sensitive: C3 – Early Trials
FLT3 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C4 – Case Studies
FLT3 mutation
AML
MEK inhibitor + FLT3 inhibitor
Sensitive: D – Preclinical
FLT3 mutation
AML
sorafenib + LY3009120
Sensitive: D – Preclinical
FLT3 mutation
AML
PF-02545920
Sensitive: D – Preclinical
FLT3 mutation
AML
5-fluorouracil
Sensitive: D – Preclinical
FLT3 mutation
AML
quizartinib + IACS-010759
Sensitive: D – Preclinical
FLT3 mutation
AML
AG-1296
Sensitive: D – Preclinical
FLT3 mutation
CML
sunitinib
Sensitive: D – Preclinical
FLT3 mutation
AML
SU5614
Sensitive: D – Preclinical
FLT3 mutation
AML
ASP7487 + NT-157
Sensitive: D – Preclinical
FLT3 mutation
AML
venetoclax + olaparib
Sensitive: D – Preclinical
FLT3 mutation
AML
OTS167
Sensitive: D – Preclinical